Literature DB >> 25976317

Transformation of acidic poorly water soluble drugs into ionic liquids.

Anja Balk1, Johannes Wiest1, Toni Widmer2, Bruno Galli3, Ulrike Holzgrabe1, Lorenz Meinel4.   

Abstract

Poor water solubility of active pharmaceutical ingredients (API) is a major challenge in drug development impairing bioavailability and therapeutic benefit. This study is addressing the possibility to tailor pharmaceutical and physical properties of APIs by transforming these into tetrabutylphosphonium (TBP) salts, including the generation of ionic liquids (IL). Therefore, poorly water soluble acidic APIs (Diclofenac, Ibuprofen, Ketoprofen, Naproxen, Sulfadiazine, Sulfamethoxazole, and Tolbutamide) were converted into TBP ILs or low melting salts and compared to the corresponding sodium salts. Free acids and TBP salts were characterized by NMR and IR spectroscopy, DSC and XRPD, DVS and dissolution rate measurements, release profiles, and saturation concentration measurements. TBP salts had lower melting points and glass transition temperatures and dissolution rates were improved up to a factor of 1000 as compared to the corresponding free acid. An increase in dissolution rates was at the expense of increased hygroscopicity. In conclusion, the creation of TBP ionic liquids or solid salts from APIs is a valuable concept addressing dissolution and solubility challenges of poorly water soluble acidic compounds. The data suggested that tailor-made counterions may substantially expand the formulation scientist's armamentarium to meet challenges of poorly water soluble drugs.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dissolution rate; Hygroscopic; Ionic liquid; Pharmaceutical salts; Poorly water soluble drugs

Mesh:

Substances:

Year:  2015        PMID: 25976317     DOI: 10.1016/j.ejpb.2015.04.034

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Oral Drug Delivery Technologies-A Decade of Developments.

Authors:  G Kaur; M Arora; M N V Ravi Kumar
Journal:  J Pharmacol Exp Ther       Date:  2019-04-22       Impact factor: 4.030

2.  Ionic Liquid Pilocarpine Analog as an Antiglaucoma Drug Candidate.

Authors:  Juan Wang; Boxuan Li; Jing Tang; Li Qiu; Xin Qiao; Na Xu; Hu Yang
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-08

Review 3.  Drug-Rich Phases Induced by Amorphous Solid Dispersion: Arbitrary or Intentional Goal in Oral Drug Delivery?

Authors:  Kaijie Qian; Lorenzo Stella; David S Jones; Gavin P Andrews; Huachuan Du; Yiwei Tian
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

4.  Anticrystal Engineering of Ketoprofen and Ester Local Anesthetics: Ionic Liquids or Deep Eutectic Mixtures?

Authors:  Anita Umerska; Klaudia Bialek; Julija Zotova; Marcin Skotnicki; Lidia Tajber
Journal:  Pharmaceutics       Date:  2020-04-17       Impact factor: 6.321

5.  Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure.

Authors:  Erin Tay; Tri-Hung Nguyen; Leigh Ford; Hywel D Williams; Hassan Benameur; Peter J Scammells; Christopher J H Porter
Journal:  Pharmaceutics       Date:  2019-12-22       Impact factor: 6.321

Review 6.  The Role of Ionic Liquids in the Pharmaceutical Field: An Overview of Relevant Applications.

Authors:  Sónia N Pedro; Carmen S R Freire; Armando J D Silvestre; Mara G Freire
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

7.  Development of a gliclazide ionic liquid and its mesoporous silica particles: an effective formulation strategy to improve oral absorption properties.

Authors:  Bijian Zhou; Dan Teng; Jinghui Li; Yanhong Zhang; Minghui Qi; Minghuang Hong; Guo-Bin Ren
Journal:  RSC Adv       Date:  2022-01-05       Impact factor: 3.361

Review 8.  Ionic liquids for addressing unmet needs in healthcare.

Authors:  Christian Agatemor; Kelly N Ibsen; Eden E L Tanner; Samir Mitragotri
Journal:  Bioeng Transl Med       Date:  2018-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.